Furthermore, using KRASG12C mutant CRC patient-derived xenografts, they found that the combination of sotorasib and cetuximab, an EGFR monoclonal antibody, produced profound tumour regression which was absent with either agent alone. Here, EGFR is linked to colorectal carcinoma.